Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.2.1.23 (
beta-galactosidase
)
14,648
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A cloned complementary DNA sequence has been isolated from a human placental cDNA library in the bacteriophage expression vector lambda gt11 after screening with polyclonal antibodies against human placental
aromatase
-system cytochrome P-450 (P-450Arom). A single recombinant clone, lambda hAROM1, was characterized by its ability to generate a
beta-galactosidase
fusion protein that reacted independently with polyclonal antibodies raised against
beta-galactosidase
and cytochrome P-450Arom and with monoclonal antibodies specific for cytochrome P-450Arom. The cDNA insert, which was found to be 1.8 kilobases in length, was radiolabeled and used to analyze poly(A)+ RNA isolated from human placenta and total RNA isolated from human adipose stromal cells cultured in the absence or presence of regulatory factors. The radiolabeled cDNA hybridized to several size species of mRNA in both placental and adipose stromal cell RNA fractions. Changes in the levels of adipose stromal cell RNA that hybridized to the cDNA insert were associated with comparable changes in the levels of translatable cytochrome P-450Arom mRNA and
aromatase
system activity. These findings are indicative that lambda hAROM1 contains DNA sequences complementary to human cytochrome P-450Arom mRNA and are suggestive that regulatory factors affect
aromatase
activity by altering the transcriptional activity of the cytochrome P-450Arom gene.
...
PMID:Isolation and characterization of a complementary DNA specific for human aromatase-system cytochrome P-450 mRNA. 301 30
By mid-August 1995, 55% of broiler embryos in North America were vaccinated for Marek's disease using the INOVOJECT system, with 201 INOVOJECT machines placed with 16 of the top 25 poultry producers, providing the industry with the capacity to inject in excess of 400 million eggs per month or about 5 billion eggs per annum. In ovo administration of a bursal disease antibody-infectious bursal disease virus (BDA-IBDV) complexed vaccine to specific-pathogen-free (SPF) embryos was safer and more potent than conventional IBDV vaccine alone because it delayed the appearance of bursal lesions, produced no early mortality, produced higher geometric mean antibody titers against IBDV, and generated protective immunity against challenge. In ovo administration of a BDA-IBDV complexed vaccine to broiler embryos generated antibody titers against IBDV sooner than conventional virus vaccinates, and generated protective immunity against challenge Direct DNA injection of plasmid DNA encoding
beta-galactosidase
into breast muscle in ovo and posthatch was an effective means to achieve both gene transfer and expression, with potential for the development of gene vaccines using plasmids encoding protective antigens from poultry pathogens. In ovo administration of 800 U chicken myelomonocytic growth factor (cMGF), a chicken hematopoietic cytokine for cells of the monocytic-granulocytic lineages, significantly reduced mortality associated with Escherichia coli exposure within the hatcher when compared to PBS controls (6.1 vs 12.4, P < or = 0.05), but not when compared to a yeast expression control. A procedure was developed enabling injection prior to the onset of incubation without compromising embryo viability. This in ovo injection process has opened up the window of embryo development during incubation for intervention, as illustrated by the 100% male phenotype produced in chicks hatching from eggs injected with
aromatase
inhibitor prior to incubation. These data illustrate some of the in ovo applications presently in use by the poultry industry, and under development or in research at EMBREX.
...
PMID:Applications in in ovo technology. 903 3
Estrogen-related receptor (ERR) alpha-1 shares a high amino acid sequence homology with estrogen receptor alpha. Although estrogens are not ligands of ERR alpha-1, our recent results suggest that toxaphene and chlordane, two organochlorine pesticides with estrogen-like activity, behave as antagonists for this orphan nuclear receptor. The two compounds increased ERR alpha-1-mediated expression of the reporter enzyme
beta-galactosidase
in a yeast-based assay. The screen was developed by expressing the hERR alpha-1-yeast Gal 4 activation domain fusion protein in yeast cells carrying the
beta-galactosidase
reporter plasmid, which contains an ERR alpha-1-binding element. In transfection experiments using mammalian cell lines, such as the SK-BR-3 breast cancer cell line, the compounds were found to have an antagonist activity against ERR alpha-1-mediated expression of the reporter chloramphenicol acetyltransferase. In contrast to the findings with ERR alpha-1, the two compounds were found to slightly induce the estrogen receptor a-mediated expression of chloramphenicol acetyltransferase in SK-BR-3 cells. In a ligand-independent manner, the ERR alpha-1 activity in SK-BR-3 cells was induced 3-fold by cotransfection with the GRIP1 coactivator expression plasmid. Toxaphene was found to be capable of suppressing the GRIP1 coactivator-induced ERR alpha-1 activity in SK-BR-3 cells. In addition, a stable ERR alpha-1 expressing HepG2 hepatoma cell line was generated, and the
aromatase
activity in the transfected cell line was found to be twice that in the untransfected cell line. The enzyme
aromatase
converts androgens to estrogens, and
aromatase
expression in HepG2 cells is regulated in part by an ERR alpha-1-modulating promoter. A 24-h incubation of an ERR alpha-1-transfected HepG2 cell line with 10 microM toxaphene reduced its
aromatase
activity to the level in the untransfected cell line. Because toxaphene is not an inhibitor of
aromatase
, it is thought that the decrease of the
aromatase
activity in ERR alpha-1 transfected HepG2 cells following toxaphene treatment resulted from a suppression of the
aromatase
expression by toxaphene acting as the antagonist of ERR alpha-1. Toxaphene and chlordane are among the 12 persistent organic pollutants identified by the United Nations Environment Programme as requiring urgent attention. Their antagonistic effects on ERR alpha-1 should not be overlooked.
...
PMID:Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor. 1049 99
Tamoxifen has contributed to a dramatic reduction in breast cancer mortality and recent results indicate that
aromatase
inhibitors may further improve survival in some patients. Nevertheless, a substantial proportion of patients become resistant to treatment. To date, with the exception of estrogen receptor (ER) determination by ligand binding or immunohistochemical techniques, there has been no way of predicting which of several therapies is indicated in particular patients. We describe a novel assay using the adenoviral gene delivery system to assess ER function in breast cancer cells derived directly from patients. The purification and short-term culture of these cells has been recently described by our laboratory. Adenovirus containing an estrogen-regulated
beta-galactosidase
reporter gene (ERE-lacZ) was constructed and used to test ER activity in breast cancer cells derived from 18 patients with primary and 16 patients with metastatic cancer, under varying treatment schedules. The adenoviral assay enabled ER activity to be readily determined in purified cells from primary breast cancers and secondary sites. Breast cancers cells could be categorized on the basis of ER activity in the absence of ligand, the presence of estrogen or anti-estrogens. In primary breast cancers, our results correlated with ER determination by immunohistochemistry in 78% of cases. In patients who had become resistant to tamoxifen, however, we found some in whom reporter activity was stimulated by tamoxifen and others whose tumors were either still estrogen responsive or completely unresponsive, irrespective of the original ER content. Our findings indicate that this reporter assay could be useful in decisions regarding use of adjuvant endocrine therapies in breast cancer.
...
PMID:Reporter gene assay demonstrates functional differences in estrogen receptor activity in purified breast cancer cells: a pilot study. 1456 18
The expression of human placental
aromatase
is transcriptionally regulated through the promoter region of exon 1a (I.1) of the gene. We examined the transcriptional regulation by using human choriocarcinoma-derived JEG-3 cells which also express aromatase mRNA transcribed under the control of the placenta-specific promoter of the exon 1a. Aromatase in the cells was induced by forskolin (cAMP) and phorbol ester (TPA) in both levels of the activity and the mRNA. However, any elements responsible for the cAMP-responsiveness have not yet identified. To identify and characterize the specific elements, CAT assay of the placenta-specific promoter was performed. We reconstructed an 11.5 kb gene structure consisting of exons 1a (I.1), 1b (I.4), 1c (I.3), and 1d (PII) and their proximal promoter regions to mimic the native structure of human
aromatase
gene and performed a promoter assay by the transient expression of a CAT reporter carrying the mini-gene structure. The construct was transcribed from exon 1a in JEG-3 cells and exon 1b in HepG2 cells to produce tissue-specific mRNAs from the exons 1-CAT hybrid gene, indicating that the mini-gene structure contained promoter regions essential for the tissue-specific expression. However, unexpectedly exons 1-CAT hybrid mRNA in JEG-3 cells was not induced by forskolin. Then, we prepared JEG-3 cells transformed by incorporation of the exons 1-CAT hybrid gene into the chromosomal DNA. The cells stably expressed the hybrid reporter gene which was transcribed from exon 1a and induced by forskolin and TPA. These results suggest that enhancers on the promoter regions of exons 1b, 1c, and 1d might interact with a transcriptional machinery of exon 1a in the induction by forskolin and TPA. Finally, a
beta-galactosidase
gene connected with the 11.5 kb gene structure was introduced into mouse eggs to produce transgenic mice. The hybrid gene was transcribed from exon 1c in the gonadal tissues of all lines of the transgenic mice in accordance with the tissue-specificity of human
aromatase
gene, whereas it was not transcribed from exon 1a, but from exons 1b and 1c in the all placentae. The results suggest that the mouse placenta might lack in the transcriptional elements or factors essential for the placenta-specific expression of human
aromatase
gene.
...
PMID:Unique regulation of expression of human aromatase in the placenta. 1462 29